New Antibody-Drug conjugate KIVU-107 enters first human trials for Hard-to-Treat cancers
NCT ID NCT07229313
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called KIVU-107 in 76 adults with advanced solid tumors that have not responded to standard treatments. KIVU-107 is an antibody-drug conjugate designed to target and kill cancer cells. The main goal is to find a safe dose and check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KIVU-107 (an antibody-drug conjugate targeting PTK7)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is a very early (Phase 1) and small trial (76 people), so safety and effectiveness are not yet known. The drug may cause side effects or not shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kivu Trial Site
RECRUITINGSanta Monica, California, 90403, United States
-
Kivu Trial Site
RECRUITINGCamperdown, New South Wales, 2050, Australia
-
Kivu Trial Site
RECRUITINGSydney, New South Wales, Australia
-
Kivu Trial Site
RECRUITINGBrisbane, Queensland, Australia
-
Kivu Trial Site
RECRUITINGAdelaide, South Australia, Australia
-
Kivu Trial Site
RECRUITINGGeelong, Victoria, Australia